45M newly diagnosed with HFrEF, EF 30%. Currently on low-dose metoprolol succinate started by a referring physician. BP is 110/70, HR 72, eGFR 58, K+ 4.2. The 2022 AHA/ACC guidelines now recommend quadruple therapy with ACEi/ARNI, beta-blocker, MRA, and SGLT2i. What is the preferred sequencing to initiate these four pillars, and how do you manage potassium monitoring when adding spironolactone in CKD stage 3?
For peer discussion only — not a substitute for clinical judgment. Verify with authoritative sources.
1 Answer
The 2022 AHA/ACC Heart Failure Guidelines recommend initiating all four pillars of GDMT simultaneously or in rapid succession rather than sequential up-titration. Practical sequencing for a stable outpatient like this: 1. Continue beta-blocker (metoprolol succinate already started — continue and uptitrate to target dose of 200mg/day) 2. Start ACEi (e.g., ramipril 2.5mg BD) or consider ARNI (sacubitril/valsartan) if tolerated — do not use ACEi + ARNi simultaneously 3. Start SGLT2i (dapagliflozin 10mg OD or empagliflozin 10mg OD) — renal and cardiac benefit, helps protect eGFR 4. Add MRA (spironolactone 25mg OD) with careful monitoring For MRA initiation in CKD Stage 3 (eGFR 58): - Acceptable to start spironolactone if K+ <5.0 mEq/L and eGFR >30 - Check K+ and renal function at 1 week, 4 weeks, then every 3 months - Hold MRA if K+ >5.5 or eGFR drops >30% from baseline - Consider patiromer (K+ binder) prophylactically if at high hyperkalemia risk Target doses: carvedilol 25mg BD / metoprolol succinate 200mg OD; ramipril 5–10mg BD; spironolactone 25–50mg OD; dapagliflozin 10mg OD.
Your Answer
Be specific. Your credentials will be shown with your answer.